五个高收入国家子宫内膜异位症诊疗组织模式的比较分析:对卫生系统与政策的意义
本研究比较澳大利亚、丹麦、德国、荷兰和英国五个高收入国家在初级、二级和三级层面子宫内膜异位症诊疗的组织方式。各国均已采取由经验丰富的多学科团队提供诊疗的举措,但二级和三级中心的认证标准差异很大;仅在丹麦,二级中心必须将晚期子宫内膜异位症患者转诊至三级中心。该概述可为国家层面诊疗框架的制定提供参考。
要点
- 五国均已有由经验丰富的多学科团队提供子宫内膜异位症诊疗的举措。
- 二级和三级中心的认证标准在各国之间差异很大。
- 五国均未将子宫内膜异位症自动认定或登记为慢性病。
核心结论
- 所有研究国家均已采取举措由经验丰富的多学科团队提供子宫内膜异位症诊疗,但二级和三级中心的认证标准在各国之间差异很大。
研究设计与样本
- 研究纳入五个已将子宫内膜异位症诊疗在一定程度上集中化或已制定国家行动计划的高收入国家:澳大利亚、丹麦、德国、荷兰和英国。
- 信息通过同行评议文献和灰色文献综述收集,并由各国专家修订和补充。
主要发现
- 2018年澳大利亚启动了政府主导的子宫内膜异位症综合国家行动计划。
- 德国二级和三级子宫内膜异位症诊疗按三个层级组织,丹麦和荷兰采用两级体系,英国迄今仅启动了三级转诊中心。
- 仅在丹麦,二级诊疗中心必须将晚期子宫内膜异位症患者转诊至三级诊疗中心。
- 在所有研究国家,晚期子宫内膜异位症的治疗也在未经认证的中心进行,这些中心的诊疗质量未经过评估。
- 澳大利亚和英国已启动并运行国家子宫内膜异位症登记系统;在所研究国家中,均未将子宫内膜异位症自动认定或登记为慢性病。
关键数值与推荐
- 各国已采取多种举措加强卫生专业人员的培训、向患者提供信息并提高对子宫内膜异位症的认识。
临床怎么用
- 本概述可为政策制定者在制定本国子宫内膜异位症诊疗组织框架时提供建议和指导。
局限性
- 五个评估国家仍在持续努力进一步改进子宫内膜异位症诊疗的组织。
- 随着服务提供、资源配置和卫生保健结构的不断修订,本概述应视为截至2025年初的快照。
- 本概述主要依赖科学文献、政策文件和专家意见,而非客观结局,因此所总结内容与实际临床实践之间可能存在不同步。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: How is endometriosis care organized at the primary, secondary, and tertiary care levels in five high-income countries? SUMMARY ANSWER: In all countries under study, initiatives have been taken to provide endometriosis care by experienced health care professionals in a multidisciplinary setting, but certification criteria for secondary and tertiary centres vary greatly across countries. WHAT IS KNOWN ALREADY: Endometriosis is a highly prevalent and complex disease with potentially significant physical, sexual, psychological, social, and economic impacts on those affected. Logically, a multidisciplinary approach by health care providers with expertise and experience has been recommended. STUDY DESIGN, SIZE, DURATION: This study included five high-income countries where endometriosis care was centralized to some extent or where a national action plan for endometriosis was developed. PARTICIPANTS/MATERIALS, SETTING, METHODS: Based on a review of the literature, five countries were selected: Australia, Denmark, Germany, the Netherlands, and the UK. Information was collected through a review of peer-reviewed and grey literature that was revised and amended by experts from each country. MAIN RESULTS AND THE ROLE OF CHANCE: In 2018, Australia launched a comprehensive government-led national action plan for endometriosis. In Germany, secondary and tertiary endometriosis care is organized at three levels, while in Denmark and the Netherlands, a two-level system has been installed, whereas in the UK, only tertiary referral centres have been initiated to date. Only in Denmark must secondary care centres refer patients with advanced endometriosis to tertiary care centres. In all countries studied, treatment for advanced endometriosis is also carried out in centres without certification, where the quality of care is not assessed. National endometriosis registries have commenced and are active in Australia and the UK. In the selected countries, various initiatives have been taken to enhance the training of health care professionals, to inform patients, and to increase awareness on endometriosis. In none of the studied countries is endometriosis (automatically) recognized and/or registered as a chronic condition. LIMITATIONS, REASONS FOR CAUTION: In the five countries evaluated, there are continuing efforts to further improve the organization of endometriosis care. With ongoing revisions of service provision, resourcing and health care structures for endometriosis are evolving considerably; therefore, this overview should be considered as a snapshot taken up to early 2025. Since this overview relies principally on scientific literature, policy documents, and expert opinions, and not on objective outcomes, there may be dyssynchrony between what is summarized here and actual clinical practice. WIDER IMPLICATIONS OF THE FINDINGS: This overview may provide advice and guidance for policy makers in the development of a framework for the organization of endometriosis care in their country. STUDY FUNDING/COMPETING INTEREST(S): The research was supported by the government-approved work program of the Belgian Health Care Knowledge Centre (KCE). C.N. is funded though the NECST Network grant (4-I66SNMA) from the Australian Government Department of Health and Aged Care, manages research grant funding from the MRFF, is Chair of the Australian Clinical Trials Alliance (ACTA) Special Interest Group for Network Managers (SIGNet) and was a previous employee with CSL Vifor (formerly Vifor Pharma Pty. Ltd). J.A. is on advisory boards and received consulting fees from Gedeon Richter, BD and Hologic, received honoraria for lectures from MSD and Hologic, and received support for attending meetings from Hologic. He is on the Endometriosis Advisory Group for the Australian Government, Chaired the first Australian Guidelines for Endometriosis Diagnosis and Management, and contributed to the Governments National Action Plan on Endometriosis. He is the Chair of the NECST Network, past-President of AGES, and past-Chair and Medical Director of Endometriosis Australia and holds multiple competitive grants in endometriosis research through Australian Government funding agencies (Commonwealth Department of Health and Aged Care, MRFF), AGES, Country Women's Association of NSW, MSD and Endometriosis Australia. R.L., N.B., C.C., F.D., M.D.J., D.H., A.K., A.N., S.O., and K.-W.S. have no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.
引用
- Leroy R, Abbott J, Benahmed N, et al. Comparative analysis of the organization of endometriosis care in five high-income countries: implications for health systems and policy. Hum Reprod. 2025. PMID: 41091783. doi:10.1093/humrep/deaf190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。